Methylxanthines, Leukotriene Modifiers, and Mast Cell Stabilizers

Theophylline produces bronchodilation through two complementary mechanisms. The primary mechanism at therapeutic concentrations is inhibition of phosphodiesterase 3 and phosphodiesterase 4 in airway smooth muscle and inflammatory cells. By blocking cyclic AMP degradation, theophylline raises intracellular cyclic AMP, activates protein kinase A, and produces bronchodilation — the same final pathway as beta-2 agonists, but reached via a different upstream target. Phosphodiesterase 4 inhibition in inflammatory cells adds a modest anti-inflammatory effect that is separate from bronchodilation.

The second mechanism is non-competitive antagonism of adenosine receptors — primarily A1 and A2B subtypes. Adenosine acting at A1 receptors promotes bronchoconstriction and acting at A2B receptors on mast cells triggers histamine release. Theophylline blockade of both contributes to bronchodilation and reduced mast cell degranulation at therapeutic concentrations. At higher concentrations, adenosine receptor antagonism also produces the cardiac and central nervous system toxicities that define theophylline's danger profile.

Theophylline exhibits Michaelis-Menten (saturable, zero-order at therapeutic concentrations) kinetics, meaning that small increases in dose produce disproportionately large increases in plasma concentration once the metabolizing enzymes approach saturation. This non-linear relationship is the pharmacokinetic basis for theophylline's danger: a dose that is safe one day may become toxic the next if a drug interaction, illness, or change in smoking status alters clearance.

The therapeutic window is 10 to 20 micrograms per milliliter. Below 10 micrograms per milliliter, bronchodilatory efficacy is limited. Above 20 micrograms per milliliter, toxicity becomes likely. The margin between therapeutic and toxic concentrations is narrow enough that therapeutic drug monitoring is mandatory for any patient receiving scheduled theophylline. Aminophylline is the intravenous prodrug form — a theophylline-ethylenediamine salt that is approximately 80% theophylline by weight; doses are calculated accordingly.

Arachidonic acid is released from membrane phospholipids by phospholipase A2, which is activated in mast cells, eosinophils, and other inflammatory cells during allergen challenge or airway injury. Arachidonic acid is then metabolized through two competing pathways: the cyclooxygenase pathway produces prostaglandins and thromboxanes; the 5-lipoxygenase pathway produces leukotrienes. 5-lipoxygenase requires its activating protein (5-lipoxygenase-activating protein, FLAP) to function; FLAP anchors 5-lipoxygenase to the nuclear membrane and presents arachidonic acid to the enzyme. Inhibiting FLAP prevents 5-lipoxygenase from accessing its substrate — an alternative therapeutic target to direct enzyme inhibition.

5-lipoxygenase converts arachidonic acid to leukotriene A4, which is then conjugated with glutathione to form leukotriene C4. Sequential peptide cleavage produces leukotriene D4 and leukotriene E4 — together these three are the cysteinyl leukotrienes. Leukotriene D4 is the most potent bronchoconstrictor of the three and acts at CysLT1 receptors on airway smooth muscle to produce bronchoconstriction 100 to 1000 times more potently than histamine on a molar basis. Beyond bronchoconstriction, cysteinyl leukotrienes increase vascular permeability, stimulate mucus secretion, recruit eosinophils, and promote airway remodeling.

Cromolyn sodium and nedocromil inhibit mast cell degranulation, preventing the release of histamine, cysteinyl leukotrienes, and other mediators in response to allergen challenge. Their precise molecular mechanism involves blockade of chloride channels in mast cell membranes, stabilizing the cell against activation signals. Both are inhaled agents with an excellent safety profile — they have no systemic adverse effects of significance — but require four-times-daily dosing and produce less anti-inflammatory efficacy than even low-dose inhaled corticosteroids. They are now rarely used in adults, with a residual role in children with mild asthma where parents are particularly concerned about corticosteroid adverse effects, and in exercise-induced bronchoconstriction prophylaxis when inhaled corticosteroids are not tolerated.

Aspirin-exacerbated respiratory disease is a clinical triad of asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity reactions to aspirin and other nonsteroidal anti-inflammatory drugs. The pathophysiology is pharmacological rather than immunological: inhibition of cyclooxygenase-1 by aspirin and nonsteroidal anti-inflammatory drugs blocks the prostaglandin E2 production that normally restrains leukotriene synthesis and mast cell activation. With prostaglandin E2 removed, arachidonic acid is shunted through the 5-lipoxygenase pathway, producing a surge of cysteinyl leukotrienes that triggers bronchoconstriction, nasal symptoms, and urticaria within 30 to 180 minutes of aspirin ingestion.

Because the reaction is pharmacological rather than IgE-mediated, it occurs with all cyclooxygenase-1 inhibitors and not just aspirin specifically. Acetaminophen at doses below 1 gram and celecoxib (a selective cyclooxygenase-2 inhibitor) at standard doses are generally safe alternatives. Management centers on nonsteroidal anti-inflammatory drug avoidance, nasal corticosteroids, leukotriene receptor antagonists (which blunt the leukotriene surge), and sinus surgery for polyp burden. Aspirin desensitization — performed at specialized centers — can allow aspirin tolerance in patients who require antiplatelet therapy for cardiovascular indications.